Collecting duct carcinoma (CDC), or Bellini duct carcinoma, is a rare and aggressive subtype of renal cell carcinoma, accounting for 0.2% - 1% of cases. It often presents at an advanced stage with nonspecific symptoms, requiring histopathology for diagnosis. Surgery remains the standard of care for localized disease, serving both diagnostic and therapeutic purposes, though adjuvant chemotherapy has shown limited efficacy. In metastatic CDC, the gemcitabine-cisplatin regimen is commonly used due to its resemblance to urothelial cancer and supportive data from prospective studies. Newer therapies offer promise in advanced cases. Immune checkpoint inhibitors, such as nivolumab alone or with ipilimumab, have shown benefits in patients with high PD-L1 expression. Targeted therapies like cabozantinib demonstrated efficacy and safety as first-line treatments in phase II trials, while sunitinib and sorafenib have shown responses in various case reports and cohorts. However, combining chemotherapy with bevacizumab did not improve outcomes in phase II trials. Despite therapeutic advances in urothelial cancers and clear cell renal tumors, the CDC entity remains a challenging malignancy, emphasizing the need for continued research to understand the true efficacy of treatment and to prolong survival in advanced disease.
References
[1]
Fleming, S. and Lewi, H.J.E. (1986) Collecting Duct Carcinoma of the Kidney. Histopathology, 10, 1131-1141. https://doi.org/10.1111/j.1365-2559.1986.tb02553.x
[2]
Saad, A.M., Gad, M.M., Al-Husseini, M.J., Ruhban, I.A., Sonbol, M.B. and Ho, T.H. (2019) Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A Seer-Based Study. ClinicalGenitourinaryCancer, 17, 46-57.e5. https://doi.org/10.1016/j.clgc.2018.10.002
[3]
Tang, C., Zhou, Y., Ge, S., Yi, X., Lv, H. and Zhou, W. (2021) Incidence, Clinical Characteristics, and Survival of Collecting Duct Carcinoma of the Kidney: A Population-Based Study. FrontiersinOncology, 11, Article 727222. https://doi.org/10.3389/fonc.2021.727222
[4]
Tokuda, N., Naito, S., Matsuzaki, O., Nagashima, Y., Ozono, S. and Igarashi, T. (2006) Collecting Duct (Bellini Duct) Renal Cell Carcinoma: A Nationwide Survey in Japan. JournalofUrology, 176, 40-43. https://doi.org/10.1016/s0022-5347(06)00502-7
[5]
Voss, J.N., Nkwam, N.M., McCulloch, T.A. and Mann, G.S. (2016) Collecting Duct Carcinoma with Cardiac Metastases: A Case Report & Literature Review. UrologyCaseReports, 5, 27-30. https://doi.org/10.1016/j.eucr.2015.12.010
[6]
Humphrey, P.A., Moch, H., Cubilla, A.L., Ulbright, T.M. and Reuter, V.E. (2016) The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. EuropeanUrology, 70, 106-119. https://doi.org/10.1016/j.eururo.2016.02.028
[7]
Powles, T., Albiges, L., Bex, A., Comperat, E., Grünwald, V., Kanesvaran, R., et al. (2024) Renal Cell Carcinoma: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. AnnalsofOncology, 35, 692-706. https://doi.org/10.1016/j.annonc.2024.05.537
[8]
Bates, C., Ho, J. and Sims-Lucas, S. (2014) Embryonic Development of the Kidney. In: Avner, E., Harmon, W., Niaudet, P., Yoshikawa, N., Emma, F. and Goldstein, S., Eds., PediatricNephrology, Springer, 1-41. https://doi.org/10.1007/978-3-642-27843-3_1-1
[9]
Antonelli, A., Portesi, E., Cozzoli, A., Zanotelli, T., Tardanico, R., Balzarini, P., et al. (2003) The Collecting Duct Carcinoma of the Kidney: A Cytogenetical Study. EuropeanUrology, 43, 680-685. https://doi.org/10.1016/s0302-2838(03)00152-0
[10]
Vázquez-Lavista, L.G., Uribe-Uribe, N. and Gabilondo-Navarro, F. (2008) Collecting Duct Renal Cell Carcinoma: Two Different Clinical Stages, Two Different Clinical Outcomes. UrologiaInternationalis, 81, 116-118. https://doi.org/10.1159/000137652
[11]
Chao, D., Zisman, A., Pantuck, A.J., Gitlitz, B.J., Freedland, S.J., Said, J.W., et al. (2002) Collecting Duct Renal Cell Carcinoma: Clinical Study of a Rare Tumor. JournalofUrology, 167, 71-74. https://doi.org/10.1016/s0022-5347(05)65385-2
[12]
Pagani, F., Colecchia, M., Sepe, P., Apollonio, G., Claps, M., Verzoni, E., et al. (2019) Collecting Ducts Carcinoma: An Orphan Disease. Literature Overview and Future Perspectives. CancerTreatmentReviews, 79, Article ID: 101891. https://doi.org/10.1016/j.ctrv.2019.101891
[13]
Staehler, M., Schöppler, G., Haseke, N., Stadler, T., Karl, A., Siebels, M., et al. (2009) Carcinoma of the Collecting Ducts of Bellini of the Kidney: Adjuvant Chemotherapy Followed by Multikinase Inhibition with Sunitinib. ClinicalGenitourinaryCancer, 7, 58-61. https://doi.org/10.3816/cgc.2009.n.010
[14]
Panunzio, A., Sorce, G., Tappero, S., Hohenhorst, L., Cano Garcia, C., Piccinelli, M., et al. (2023) Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma. ClinicalGenitourinaryCancer, 21, 295-300. https://doi.org/10.1016/j.clgc.2022.08.010
[15]
Oudard, S., Banu, E., Vieillefond, A., Fournier, L., Priou, F., Medioni, J., et al. (2007) Prospective Multicenter Phase II Study of Gemcitabine Plus Platinum Salt for Metastatic Collecting Duct Carcinoma: Results of a GETUG (Groupe D’etudes Des Tumeurs Uro-Génitales) Study. JournalofUrology, 177, 1698-1702. https://doi.org/10.1016/j.juro.2007.01.063
[16]
Dason, S., Allard, C., Sheridan-Jonah, A., Gill, J., Jamshaid, H., Aziz, T., et al. (2013) Management of Renal Collecting Duct Carcinoma: A Systematic Review and the Mcmaster Experience. CurrentOncology, 20, 223-232. https://doi.org/10.3747/co.20.1230
[17]
Bagrodia, A., Gold, R., Handorf, C., Liman, A. and Derweesh, I.H. (2008) Salvage Paclitaxel Chemo-Therapy for Metastatic Collecting Duct Carcinoma of the Kidney. The Canadian Journal of Urology, 15, 4425-4427.
[18]
Gollob, J.A., Upton, M.P., DeWolf, W.C. and Atkins, M.B. (2001) Long-Term Remission in a Patient with Metastatic Collecting Duct Carcinoma Treated with Taxol/Carboplatin and Surgery. Urology, 58, Article No. 1058. https://doi.org/10.1016/s0090-4295(01)01411-x
[19]
Motzer, R.J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M. and Reuter, V. (2002) Treatment Outcome and Survival Associated with Metastatic Renal Cell Carcinoma of Non-Clear-Cell Histology. JournalofClinicalOncology, 20, 2376-2381. https://doi.org/10.1200/jco.2002.11.123
[20]
Fuu, T., Iijima, K., Kusama, Y., Otsuki, T. and Kato, H. (2022) Complete Response to Combination Therapy Using Nivolumab and Ipilimumab for Metastatic, Sarcomatoid Collecting Duct Carcinoma Presenting with High Expression of Programmed Death-Ligand 1: A Case Report. JournalofMedicalCaseReports, 16, Article No. 193. https://doi.org/10.1186/s13256-022-03426-3
[21]
Yasuoka, S., Hamasaki, T., Kuribayashi, E., Nagasawa, M., Kawaguchi, T., Nagashima, Y., et al. (2018) Nivolumab Therapy for Metastatic Collecting Duct Carcinoma after Nephrectomy. Medicine, 97, e13173. https://doi.org/10.1097/md.0000000000013173
[22]
Mizutani, K., Horie, K., Nagai, S., Tsuchiya, T., Saigo, C., Kobayashi, K., et al. (2017) Response to Nivolumab in Metastatic Collecting Duct Carcinoma Expressing PD-L1: A Case Report. MolecularandClinicalOncology, 7, 988-990. https://doi.org/10.3892/mco.2017.1449
[23]
Watanabe, K., Sugiyama, T., Otsuka, A. and Miyake, H. (2019) Complete Response to Combination Therapy with Nivolumab and Ipilimumab for Metastatic Collecting Duct Carcinoma of the Kidney. InternationalCancerConferenceJournal, 9, 32-35. https://doi.org/10.1007/s13691-019-00389-z
[24]
Procopio, G., Sepe, P., Claps, M., Buti, S., Colecchia, M., Giannatempo, P., et al. (2022) Cabozantinib as First-Line Treatment in Patients with Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). JAMAOncology, 8, 910-913. https://doi.org/10.1001/jamaoncol.2022.0238
[25]
Vera-Badillo, F.E., Templeton, A.J., Duran, I., Ocana, A., de Gouveia, P., Aneja, P., et al. (2015) Systemic Therapy for Non-Clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-Analysis. EuropeanUrology, 67, 740-749. https://doi.org/10.1016/j.eururo.2014.05.010
[26]
Procopio, G., Verzoni, E., Iacovelli, R., Colecchia, M., Torelli, T. and Mariani, L. (2012) Is There a Role for Targeted Therapies in the Collecting Ducts of Bellini Carcinoma? Efficacy Data from a Retrospective Analysis of 7 Cases. ClinicalandExperimentalNephrology, 16, 464-467. https://doi.org/10.1007/s10157-012-0589-3
[27]
Zhao, R., Nie, L., Gong, R., Wang, J., Wazir, R., Liu, L., et al. (2013) Active Targeted Therapy for Metastatic Collecting Duct Carcinoma of the Kidney: A Case Report and Review of the Literature. InternationalUrologyandNephrology, 45, 1017-1021. https://doi.org/10.1007/s11255-013-0468-1
[28]
Ansari, J., Fatima, A., Chaudhri, S., Bhatt, R.I., Wallace, M. and James, N.D. (2009) Sorafenib Induces Therapeutic Response in a Patient with Metastatic Collecting Duct Carcinoma of Kidney. OncologyResearchandTreatment, 32, 44-46. https://doi.org/10.1159/000183736
[29]
Sheng, X., Cao, D., Yuan, J., Zhou, F., Wei, Q., Xie, X., et al. (2018) Sorafenib in Combination with Gemcitabine Plus Cisplatin Chemotherapy in Metastatic Renal Collecting Duct Carcinoma: A Prospective, Multicentre, Single-Arm, Phase 2 Study. EuropeanJournalofCancer, 100, 1-7. https://doi.org/10.1016/j.ejca.2018.04.007
[30]
Pécuchet, N., Bigot, F., Gachet, J., Massard, C., Albiges, L., Teghom, C., et al. (2013) Triple Combination of Bevacizumab, Gemcitabine and Platinum Salt in Metastatic Collecting Duct Carcinoma. AnnalsofOncology, 24, 2963-2967. https://doi.org/10.1093/annonc/mdt423
[31]
Barrascout, E., Beuselinck, B., Ayllon, J., Bättig, B., Moch, H., Teghom, C., et al. (2012) Complete Remission of Pulmonary Metastases of Bellini Duct Carcinoma with Cisplatin, Gemcitabine and Bevacizumab: A Case Report. AmericanJournalofCaseReports, 13, 1-2. https://doi.org/10.12659/ajcr.882234
[32]
Thibault, C., Fléchon, A., Albiges, L., Joly, C., Barthelemy, P., Gross-Goupil, M., et al. (2023) Gemcitabine Plus Platinum-Based Chemotherapy in Combination with Bevacizumab for Kidney Metastatic Collecting Duct and Medullary Carcinomas: Results of a Prospective Phase II Trial (BEVABEL-GETUG/AFU24). EuropeanJournalofCancer, 186, 83-90. https://doi.org/10.1016/j.ejca.2023.03.018
[33]
van der Heijden, M.S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., et al. (2023) Nivolumab Plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. NewEnglandJournalofMedicine, 389, 1778-1789. https://doi.org/10.1056/nejmoa2309863
[34]
Bronchud, M.H., Castillo, S., Escriva de Romaní, S., Mourelo, S., Fernández, A., Baena, C., et al. (2012) HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report. Onkologie, 35, 776-779. https://doi.org/10.1159/000345041
